发明名称 Matrix metalloproteinase inhibitors
摘要 Compounds of Formula (I): wherein: A represents bond, C<SUB>1-6</SUB>alkyl or CH-CH-C<SUB>1-4</SUB>alkyl; B represents bond, 0, S, SO, SO<SUB>2</SUB>, CO, CR<SUP>7</SUP>R<SUP>8</SUP>, CO<SUB>2</SUB>R<SUP>14</SUP>, CONR<SUP>14</SUP>R<SUP>15</SUP>, N(COR<SUP>14</SUP>)(COR<SUP>15</SUP>), N(SO<SUB>2</SUB>R<SUP>14</SUP>)(COR<SUP>15</SUP>) or NR<SUP>14</SUP>R<SUP>15</SUP>; D represents bond, or C<SUB>1-6</SUB>alkyl; E represents substituted aryl or substituted or unsubstituted heteroaryl; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, SO, SO<SUB>2</SUB>, CO, CNR<SUP>5</SUP>, CNOR<SUP>5</SUP>, CNNR<SUP>5</SUP>R<SUP>6</SUP>, NR<SUP>11 </SUP>or CR<SUP>7</SUP>R<SUP>8</SUP>; Y represents CR<SUP>5</SUP>OR<SUP>11</SUP>, CR<SUP>5</SUP>SR<SUP>11</SUP>, NOR<SUP>5</SUP>, CR<SUP>5</SUP>NR<SUP>6</SUP>R<SUP>11</SUP>, SO, SO<SUB>2</SUB>, CO, CNR<SUP>5</SUP>, CNOR<SUP>5 </SUP>or CS; R<SUP>1 </SUP>and R<SUP>1'</SUP> each independently represents H, C<SUB>1-6</SUB>alkyl or C<SUB>1-4</SUB>alkylaryl; R<SUP>2 </SUP>represents CO<SUB>2</SUB>R<SUP>12</SUP>, CH<SUB>2</SUB>OR<SUP>12 </SUP>or CONR<SUP>12</SUP>R<SUP>13</SUP>, CONR<SUP>12</SUP>OR<SUP>13</SUP>, NR<SUP>12</SUP>COR<SUP>13</SUP>, SR<SUP>12</SUP>, PO(OH)<SUB>2</SUB>, PONHR<SUP>12 </SUP>or SONHR<SUP>12</SUP>; R<SUP>3 </SUP>represents H, C<SUB>1-6</SUB>alkyl or C<SUB>1-4</SUB>alkylaryl; R<SUP>4 </SUP>represents optionally substituted aryl or heteroaryl; Z represents a bond, CH<SUB>2</SUB>, O, S, SO, SO<SUB>2</SUB>, NR<SUP>5</SUP>, OCR<SUP>5</SUP>R<SUP>6</SUP>, CR<SUP>9</SUP>R<SUP>10</SUP>O or Z, R<SUP>4 </SUP>and Q together form an optionally substituted fused tricyclic group; R<SUP>5 </SUP>and R<SUP>6 </SUP>each independently represent H, C<SUB>1-6 </SUB>alkyl or C<SUB>1-4 </SUB>alkylaryl; R<SUP>7 </SUP>and R<SUP>8 </SUP>each independently represent H, halo, C<SUB>1-6 </SUB>alkyl or C<SUB>1-4 </SUB>alkylaryl; R<SUP>9 </SUP>and R<SUP>10 </SUP>each independently represents H, C<SUB>1-6 </SUB>alkyl optionally substituted by halo, cyano, OR<SUP>11 </SUP>or NR<SUP>6</SUP>R<SUP>11</SUP>, C<SUB>1-4 </SUB>alkylaryl optionally substituted by halo, cyano, OR11 or NR<SUP>6</SUP>R<SUP>11</SUP>, OR<SUP>11 </SUP>or, together with the N to which they are attached, R<SUP>9 </SUP>and R<SUP>10 </SUP>form a heterocyclic group: R<SUP>11 </SUP>represents H, C<SUB>1-6 </SUB>alkyl, C<SUB>1-4 </SUB>alkylaryl or COR<SUP>5</SUP>; R<SUP>12 </SUP>and R<SUP>13 </SUP>each independently represent H, C<SUB>1-3 </SUB>alkyl, C<SUB>1-3 </SUB>alkylaryl or C<SUB>1-3 </SUB>alkylheteroaryl or, together with the functionality to which they are attached, R<SUP>12 </SUP>and R<SUP>13 </SUP>form a heterocyclic group: R<SUP>14 </SUP>and R<SUP>15 </SUP>each independently represent H, C<SUB>1-6 </SUB>alkyl, C<SUB>1-4 </SUB>alkylaryl or C<SUB>1-4 </SUB>alkylheteroaryl or together with the functionality to which they are attached R<SUP>14 </SUP>and R<SUP>15 </SUP>form a heterocyclic or fused heterocyclic group; and physiologically functional derivatives thereof, corresponding processes for preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs).
申请公布号 US2006293353(A1) 申请公布日期 2006.12.28
申请号 US20060571443 申请日期 2006.03.13
申请人 GAINES SIMON;HOLMES IAN P;MARTIN STEPHEN L;WATSON STEPHEN P 发明人 GAINES SIMON;HOLMES IAN P.;MARTIN STEPHEN L.;WATSON STEPHEN P.
分类号 A61K31/513;A61K31/4035;A61K31/505;A61K31/506;A61P29/00;C07D209/48;C07D239/54;C07D403/02;C07D403/10;C07D405/10;C07D409/02 主分类号 A61K31/513
代理机构 代理人
主权项
地址